ICON PLC
ICLR
View Detailed Chart
175.000USD
-0.110-0.06%
Close 09/12, 16:00（ET）Quotes delayed by 15 min
13.61BMarket Cap
17.14P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.06%
5 Days
+0.07%
1 Month
-0.73%
6 Months
-2.21%
Year to Date
-16.55%
1 Year
-41.67%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-12Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
19
analysts
Buy
Current Rating
215.800
Target Price
+23.31%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 56.63.
Overvalued
The company’s latest PE is 17.91, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 74.28M shares, decreasing 13.23% quarter-over-quarter.
Held by Ruane Cunniff
Star Investor Ruane Cunniff holds 1.71M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.06.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
Ticker SymbolICLR
CompanyICON PLC
CEODr. Stephen (Steve) Cutler, Ph.D.
Websitehttps://www.iconplc.com/
Related Instruments
-0.94%
+1.35%
-3.38%
-1.84%
+0.10%
-7.26%
-2.70%
+1.83%
-1.40%
-1.06%
+0.20%
+0.50%
-3.68%
-1.37%
-1.67%
-1.65%
+0.67%
0.00%
-3.66%
-4.27%
